KASID
Search
- Page Path
- HOME > Search
Review
- IBD
- Targeting the gut microbiome in inflammatory bowel disease: from concept to clinical reality
- Nathalie Rolhion, Harry Sokol
- Intest Res 2025;23(4):396-404. Published online October 28, 2025
- DOI: https://doi.org/10.5217/ir.2025.00104
-
Abstract
PDF
PubReader
ePub - The gut microbiota, a complex community of trillions of microorganisms inhabiting the human gastrointestinal tract, has emerged as a critical regulator of immune homeostasis and gastrointestinal health. In the context of inflammatory bowel disease (IBD), comprising primarily Crohn’s disease and ulcerative colitis, disruptions to this microbial ecosystem—collectively termed dysbiosis—have been increasingly recognized as central to disease pathogenesis. Recent research has established that alterations in gut microbiota not only reflect disease states but may actively drive immune dysregulation, barrier dysfunction, and mucosal inflammation. This review synthesizes current knowledge on the role of the gut microbiota in IBD and evaluates the therapeutic landscape of microbiota-modulating strategies using selected examples. Fecal microbiota transplantation, while offering proof-of-concept validation, is hindered by standardization challenges and variable clinical outcomes. As a response, microbiome-based therapeutics have evolved toward defined live biotherapeutic products including bacterial consortia and single-strain products, postbiotics, and metabolite-centered approaches targeting specific pathways. Groundbreaking research into rationally designed synthetic microbiomes and next-generation probiotics is driving a paradigm shift in microbiota-based treatment for IBD from empirical to precision-guided interventions.
-
Citations
Citations to this article as recorded by
- Maternal gut microbial legacy shapes intestinal health and susceptibility of offspring to colitis
Ji-Min Lee, Min-Ji Kim, Hoyul Lee, Yujin Hyun, Sung-Wook Nam, Dong-Gyu Jeon, Jae-Ho Shin, Eun Soo Kim
npj Biofilms and Microbiomes.2026;[Epub] CrossRef - Crohn’s Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches (3rd Edition)
Dingpei Long, Junsik J. Sung
Biomedicines.2026; 14(5): 1068. CrossRef - Microbiome-Based Therapies in Ulcerative Colitis: Mechanisms, Clinical Evidence, and a Precision-Medicine Framework
Philippe Pinton
Biomedicines.2026; 14(5): 969. CrossRef - Current Understanding of Probiotic Strains and Immune Function: From Gut Microbiota to Systemic Immunity
Maciej Piotr Szota, Katarzyna Napiórkowska-Baran, Aleksandra Wojtkiewicz, Lidia Wydeheft, Adam Wawrzeńczyk, Józef Sławatycki, Paweł Treichel, Ewa Alska, Barbara Zyśk, Krzysztof Pałgan
International Journal of Molecular Sciences.2026; 27(10): 4527. CrossRef - The potential role of the gut microbiota in the development of autoantibodies associated with Spondyloarthritis: a narrative review
Alaa Elsaghir, Al-Hassan Soliman Wadan, Torsten Witte
BMC Immunology.2026;[Epub] CrossRef
- Maternal gut microbial legacy shapes intestinal health and susceptibility of offspring to colitis
- 4,516 View
- 129 Download
- 5 Web of Science
- 5 Crossref
First
Prev
